目的 探究胺碘酮对于新生儿阵发性室上性心动过速（PSVT）的疗效及安全性，为临床治疗提供依据。方法 回顾性分析2011年1月-2017年6月在梧州市工人医院治疗的PSVT新生儿病例48例，根据治疗方法分为对照组和观察组，每组24例。对照组患儿采用普罗帕酮、去乙酰毛花苷注射液等药物积极对症治疗，观察组患儿在对照组治疗基础上加用胺碘酮治疗。分析比较两组治疗效果、心电图转归、心肌标志物变化及不良反应发生情况。结果 治疗后观察组有效率为83.3%，高于对照组的62.5%，差异有统计学意义（P<0.05）。治疗后观察组心电图转归有效率为95.8%，高于对照组的70.8%，差异有统计学意义（P<0.05）。治疗前两组患儿肌红蛋白、肌钙蛋白、肌酸激酶同工酶水平差异无统计学意义；治疗后3种酶水平均有降低，同组治疗前后比较差异有统计学意义（P<0.05）；且观察组降低幅度大于对照组，差异有统计学意义（P<0.05）。两组患儿均未发生严重不良反应。结论 胺碘酮在治疗新生儿PSVT时疗效确切，安全性较高，值得临床推广使用。

Objective To investigate the efficacy and safety of amiodarone in the treatment of paroxysmal supraventricular tachycardia (PSVT) in neonates and provide the basis for clinical treatment. Methods Forty-eight neonates with paroxysmal supraventricular tachycardia treated in our hospital from January 2011 to June 2017 were retrospectively analyzed. According to the treatment methods, they were divided into control group and observation group, with 24 cases in each group. Patients in the control group were given symptomatic treatment with drugs such as cardioversion and cedilanid, while patients in the observation group were treated with amiodarone on the basis of the control group. Analysis and comparison of two groups of treatment, ECG prognosis, changes in myocardial markers and adverse reactions. Results After treatment, the effective rate of the observation group was 83.3%, which was higher than that of the control group (62.5%), the difference was statistically significant (P<0.05). After treatment, the electrocardiogram outcome rate of the observation group was 95.8%, which was higher than that of the control group 70.8%, The difference was statistically significant (P<0.05). There was no significant difference in myoglobin, troponin and creatine kinase isozyme levels between the two groups before treatment. After treatment, the levels of three enzymes decreased, but the observation group decreased more than the control group, the difference was statistically significant (P<0.05). There was no serious adverse reaction in both groups. Conclusion Amiodarone in the treatment of neonatal PSVT exact effect, and has a high safety, worthy of clinical promotion.

R969